RT Journal Article SR Electronic T1 Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.28.20157974 DO 10.1101/2020.07.28.20157974 A1 Pereda, R A1 González, D A1 Rivero, HB A1 Rivero, JC A1 Pérez, A A1 López, LR A1 Mezquia, N A1 Venegas, R A1 Betancourt, Julio Raul A1 Domínguez, RE YR 2020 UL http://medrxiv.org/content/early/2020/08/04/2020.07.28.20157974.abstract AB Background Effective antiviral treatments are required to contain the ongoing coronavirus disease 2019 (COVID-19) pandemic. A previous report in 814 patients COVID-19 positive in Cuba provided preliminary therapeutic efficacy evidence with interferon-α2b (IFN-α2b) from March 11 to April 14, 2020. This study, re-evaluates the contribution of IFN-α2b on the evolution of all patients, after 98 days of the epidemic, in a period from March 11 to June 17, 2020.Method A prospective observational study was implemented to monitor a therapeutic intervention with IFN-α2b used in the national protocol for COVID-19 attending in Cuba. Were included patients with positive throat swab specimens by real time RT-PCR who gave informed consent and had no contraindications for IFN treatment. Patients received therapy as per the Cuban COVID protocol that included a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular or subcutaneous administration of IFN-α2b The primary endpoint was the proportion of patients discharged from hospital, secondary was the case fatality rate and several outcomes related to time variables were also evaluated.Results From March 11th until June 17th, 2295 patients had been confirmed SARS-CoV-2 positive in Cuba, 2165 were treated with Heberon® Alpha R and 130 received the approved protocol without IFN. The proportion of fully recovered patients was higher in the IFN-treated compared with non-IFN treated group. Prior IFN treatment decreases the likelihood of intensive care and increases the survival after severe or critical diseases. The benefits of IFN were significantly supported by time variables analyzed.Conclusions This second report confirm the preliminary evidences from first for the therapeutic effectiveness of IFNα-2b for SARS-Cov-2 infection and postulated that Heberon® Alpha R is the main component within the antiviral triad used as a therapeutic intervention in the Cuban protocol COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRPCEC00000318Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol of this study was evaluated and approved by a centralized Research Ethics Committee, representing all hospital institutions enrolled in the diagnosis and treatment of patients. The use of Heberon Alpha in Cuban protocol was approved by the Cuban National Regulatory Authority, CECMEDAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented are from patient medical records provided by the Cuban Ministry of Public Health, in accordance with the policies established for an investigation in a pandemic scenario